Abiraterone acetate
Grumabix is a medicine that contains abiraterone acetate. It is used in adult men for the treatment of prostate cancer that has spread to other parts of the body. Grumabix works by stopping the production of testosterone in the body; this can slow down the growth of prostate cancer.
When Grumabix is used at an early stage of the disease in patients who are responding to hormone therapy, it is given together with a therapy to reduce testosterone levels (androgen deprivation therapy). During treatment with this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone. This is to reduce the risk of high blood pressure, fluid retention (oedema), or low potassium levels in the blood.
Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Grumabix.
Before taking this medicine, discuss with your doctor or pharmacist:
Tell your doctor if you have any heart or blood vessel problems, including abnormal heart rhythms (arrhythmia), or if you are taking medicines for these conditions. Tell your doctor if you have yellowing of the skin or eyes, dark urine, severe nausea or vomiting, which may be signs of liver problems. Rarely, acute liver failure can occur, which can be life-threatening. Decreased red blood cell count, decreased sex drive, muscle weakness, and/or muscle pain may occur. Grumabix must not be taken in combination with Ra-223 due to the possible increased risk of bone fractures or death. If you plan to take Ra-223 after treatment with Grumabix and prednisone/prednisolone, you should wait 5 days before starting Ra-223 treatment. If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Grumabix.
Grumabix may affect liver function, and you may not have any symptoms. During treatment with this medicine, your doctor will periodically prescribe blood tests to check the effect of the medicine on the liver.
This medicine is not used in children and adolescents. If Grumabix is accidentally swallowed by a child, you should immediately go to the hospital, taking the package leaflet with you to show to the doctor.
Before taking any medicine, consult your doctor or pharmacist. Tell your doctor or pharmacist about all medicines you are taking or have recently taken, as well as any medicines you plan to take. This is important because Grumabix may increase the effect of many medicines, including heart medicines, sedatives, certain anti-diabetic medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may need to change the dose of these medicines. Other medicines may also increase or decrease the effect of Grumabix. This may result in side effects or Grumabix not working properly. Androgen deprivation therapy may increase the risk of abnormal heart rhythms. Tell your doctor if you are taking medicines:
Tell your doctor if you are taking any of the above medicines.
It is unlikely that this medicine will affect your ability to drive or use tools or machines.
Grumabix contains lactose (a type of sugar). If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is 1000 mg (four 250 mg tablets or two 500 mg tablets) taken once a day.
Your doctor may also prescribe other medicines for you to take with Grumabix and prednisone or prednisolone.
If you take more Grumabix than you should, contact your doctor or go to the hospital immediately.
Do not stop taking Grumabix or prednisone/prednisolone without talking to your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common(may affect more than 1 in 10 people):
Swelling of the feet or ankles, low potassium levels in the blood, increased liver function test results, high blood pressure, urinary tract infections, diarrhea.
Common(may affect up to 1 in 10 people):
High lipid levels in the blood, chest pain, abnormal heart rhythms (atrial fibrillation), heart failure, rapid heart rate, severe infection - sepsis, bone fractures, indigestion, blood in the urine, rash.
Uncommon(may affect up to 1 in 100 people):
Adrenal gland problems (related to electrolyte imbalance), abnormal heart rhythm (arrhythmia), muscle weakness, and/or muscle pain.
Rare(may affect up to 1 in 1,000 people):
Lung inflammation (also known as allergic alveolitis).
Acute liver failure.
Frequency not known(frequency cannot be estimated from the available data):
Heart attack, changes in ECG (prolonged QT interval), and severe allergic reactions, causing difficulty swallowing or breathing, facial, lip, tongue, or throat swelling, or itchy rash.
Bone loss may occur in men treated for prostate cancer. Grumabix in combination with prednisone and prednisolone may increase this effect.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
You can also report side effects to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
The other ingredients are: lactose monohydrate, croscarmellose sodium, hypromellose 2910 (15 mPas), sodium lauryl sulfate, microcrystalline cellulose, silicon dioxide, magnesium stearate, polyvinyl alcohol, titanium dioxide (E 171), macrogol 4000, talc (see section 2, "Grumabix contains lactose and sodium").
Grumabix 250 mg is available in blisters containing 120 film-coated tablets. Grumabix 500 mg is available in blisters containing 60 or 120 film-coated tablets. Not all pack sizes may be marketed.
Adamed Pharma S.A.
Pieńków, ul. M. Adamkiewicza 6A
05-152 Czosnów
Adamed Pharma S.A.
ul. Marszałka Józefa Piłsudskiego 5
95-200 Pabianice
To obtain more detailed information on this medicine, contact the Marketing Authorization Holder:
Adamed Pharma S.A.
Pieńków, ul. M. Adamkiewicza 6A
05-152 Czosnów
Poland
This medicine is authorized in the Member States of the European Economic Area under the following names:
Bulgaria
ГРУМАБИКС 250 mg филмирани таблетки
ГРУМАБИКС 500 mg филмирани таблетки
Czech Republic
GRUMABIX
Denmark
GRUMABIX
France
GRUMABIX 250 mg, comprimé pelliculé
ABIRATERONE ARROW 500 mg, comprimé pelliculé
Spain
GRUMABIX 250 mg comprimidos recubiertos con película EFG
GRUMABIX 500 mg comprimidos recubiertos con película EFG
Germany
GRUMABIX
Poland
GRUMABIX
Slovakia
GRUMABIX
Hungary
GRUMABIX 250 mg filmtabletta
GRUMABIX 500 mg filmtabletta
Italy
GRUMABIX
Date of last revision of the leaflet: 06.2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.